SCHEMBL64093

SCHEMBL64093

Cc1cccc(C)c1OCCBr

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
SCN4A P35499 8/20 0.48
SCN8A Q9UQD0 5/20 0.48
LMNA P02545 3/20 0.48
SCN1A P35498 2/20 0.48
SCN5A Q14524 2/20 0.48
SCN9A Q15858 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
NFKB1 P19838 2/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48
KCNK3 O14649 1/20 0.48
CACNA1F O60840 1/20 0.48
KCNK2 O95069 1/20 0.48
GBA1 P04062 1/20 0.48
MAOA P21397 1/20 0.48
HTR2A P28223 1/20 0.48
SLC6A4 P31645 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10768133 0.89 ALDH1A1 (0.53) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL4743329 0.85 ALDH1A1 (0.56) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL23804886 0.82 TSHR (0.46) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL287638 0.81 SCN4A (0.52) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL1770541 0.80 ALDH1A1 (0.41) ALDH1A1SCN4ASCN8ALMNASCN5A
SCHEMBL1991553 0.79 ALDH1A1 (0.52) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL5592615 0.77 KMT2A (0.46) ALDH1A1LMNAHTR2AKDM4EMEN1
Ammonia Solution, Strong SCHEMBL8858388 0.77 ALDH1A1 (0.50) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL15089976 0.77 ALDH1A1 (0.50) ALDH1A1SCN4ASCN8ALMNASCN1A
SCHEMBL5824885 0.77 ALDH1A1 (0.50) ALDH1A1SCN4ASCN8ALMNASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3938345-B1 CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE NOCION THERAPEUTICS INC (US) 2026-05-06 EP disclosed
US-20250263386-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2025-08-21 US disclosed
US-20250263375-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2025-08-21 US disclosed
CN-119874561-A Charged ion channel blockers and methods of use thereof 诺西恩医疗公司 2025-04-25 CN disclosed
CN-113950471-B Charged ion channel blockers and methods of use thereof 诺西恩医疗公司 2025-01-14 CN disclosed
CN-119118953-A Charged ion channel blockers and methods of use thereof 诺西恩医疗公司 2024-12-13 CN disclosed
US-12162851-B2 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2024-12-10 US disclosed
CN-115279731-B Charged ion channel blockers and methods of use thereof 诺西恩医疗公司 2024-09-13 CN disclosed
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2023-06-22 US disclosed
US-11603355-B2 Charged ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-03-14 US disclosed
US-8129538-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-06 US disclosed
US-8129538-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-06 US disclosed
US-8129538-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-06 US disclosed
WO-2007069986-A1 NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2007-06-21 WO disclosed
EP-0232825-B1 PYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND INSECTICIDAL, ACARICIDAL, NEMATICIDAL, FUNGICIDAL COMPOSITIONS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-05-13 EP disclosed
US-4906627-A Pyridazinone derivatives, and insecticidal, acaricidal and nematicidal compositions NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1990-03-06 US disclosed
EP-0232825-A2 Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1987-08-19 EP disclosed
US-4259334-A Piperazines and therapeutic utility LAROCHE NAVARRON S.A. (FR) 1981-03-31 US disclosed
US-4166117-A HYPOTENSIVES SCIENCE UNION ET CIE (FR) 1979-08-28 US disclosed
US-4027028-A HYPOTENSIVE AGENTS SCIENCE UNION ET CIE (FR) 1977-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162851-B2 Charged ion channel blockers and methods for use TRPV1, TRPV5, TRPV2 ALDH1A1 2437/4885SCN4A 83/4885SCN8A 142/4885
US-20250263386-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV5, TRPV2 ALDH1A1 2437/4885SCN4A 83/4885SCN8A 142/4885
US-20250263375-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 ALDH1A1 2736/4885SCN4A 80/4885SCN8A 107/4885
US-11603355-B2 Charged ion channel blockers and methods for use TRPV1, TRPV2, TRPV5 ALDH1A1 2736/4885SCN4A 80/4885SCN8A 107/4885
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 ALDH1A1 2736/4885SCN4A 80/4885SCN8A 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.